Magnasense Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Marco Wititteveen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	2.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Marco Wititteveen

1.1yrs

Permanencia

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023. He has previously had multiple different roles in Med Tech and diagnosti...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bradley Messmer	Chief Scientific Officer & Member of the Board	no data	SEK 1.28m	1.39% SEK 19.4k
Marco Wititteveen	Chief Executive Officer	1.1yrs	sin datos	sin datos
Niklas Andersson	Chief Financial Officer	1.5yrs	sin datos	sin datos
Vasiliki Fragkou	Chief Operating Officer	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 52Q no se considera experimentado ( 1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bradley Messmer	Chief Scientific Officer & Member of the Board	4.4yrs	SEK 1.28m	1.39% SEK 19.4k
Seppo Makinen	Independent Member of the Board	4.4yrs	SEK 168.00k	sin datos
William Vickery	Independent Director	2.5yrs	sin datos	sin datos
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Sofia Bertling	Independent Director	2.5yrs	sin datos	sin datos
Fredrik Haglund	Independent Member of the Board	4.2yrs	SEK 48.00k	0.52% SEK 7.3k
Adam Cheifetz	Scientific Advisory Board	less than a year	sin datos	sin datos
Melissa Grant	Member of Scientific Advisory Board	no data	sin datos	sin datos

2.5yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 52Q no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Magnasense Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Recent updates

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

High number of new directors

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: €2.34

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

New 90-day high: €2.31

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad